In This Article:
ADC Therapeutics has culled its clinical asset ADCT-602 while announcing more data on its flagship drug Zynlonta (loncastuximab tesirine-lpyl).
Following the two announcements, the company’s stock, listed on the New York Stock Exchange (NYSE), closed 37.12% higher, from a $1.32 close on 13 May to a $1.81 close on 14 May.
The Swiss biotech has halted development of ADCT-602, which was being assessed in a Phase I/II trial (NCT03698552) in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL).
The trial was sponsored by the M D Anderson Cancer Center and aimed to enrol 57 patients with the hope of evaluating the safety and determining the recommended dose while also gaining information on the therapy’s efficacy by complete response (CR) with an incomplete marrow recovery rate.
The only other clinical asset in the company’s pipeline now is ADCT-701, which is currently being evaluated in a Phase I, first-in-human study (NCT06041516) in patients with neuroendocrine tumours and carcinomas. The primary objective of the trial is to determine the maximum tolerated dose.
The company also has a variety of assets in the preclinical stage of development.
New Zynlonta data
In a separate announcement on 14 May, ADC Therapeutics announced further positive data for Zynlonta, a CD19-directed antibody-drug conjugate (ADC), in combination with Roche’s Columvi (glofitamab) from the Phase Ib LOTIS-7 trial (NCT04970901).
The new data shows the combination had a 95.5% overall response rate (ORR) and 90.9% CR rate in 22 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The median duration of response (DoR) has not yet been reached.
ADC Therapeutics will be presenting the data at both the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy, in June and the 18th International Conference on Malignant Lymphoma 2025 (ICML) in Lugano, Switzerland, in July.
Zynlonta was approved through the US Food and Drug Administration’s (FDA) accelerated approval pathway in April 2021 for the treatment of DLBCL based on data from the Phase II LOTIS-2 trial (NCT03589469).
In December 2024, the company completed the Phase III LOTIS-5 study (NCT04384484), which is required as the confirmatory study to gain full approval through a supplemental biologics licence application (BLA) with the FDA. The company will also present updated LOTIS-5 safety run-in data evaluating Zynlonta plus rituximab at EHA2025.
Zynlonta also received a conditional marketing authorisation valid throughout the EU on 20 December 2022.